Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| HIV Envelope Protein gp120 | 3 | 2018 | 267 | 1.34 | Why? |
| CD4-Positive T-Lymphocytes | 7 | 2021 | 4545 | 0.94 | Why? |
| HIV Infections | 11 | 2019 | 11620 | 0.80 | Why? |
| HIV Antibodies | 5 | 2018 | 776 | 0.76 | Why? |
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2017 | 15 | 0.72 | Why? |
| HIV Long-Term Survivors | 1 | 2017 | 56 | 0.69 | Why? |
| AIDS Vaccines | 2 | 2018 | 452 | 0.65 | Why? |
| B-Lymphocytes | 2 | 2021 | 4418 | 0.55 | Why? |
| Germinal Center | 1 | 2017 | 332 | 0.54 | Why? |
| Tenofovir | 1 | 2017 | 449 | 0.52 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2017 | 497 | 0.51 | Why? |
| HIV-1 | 5 | 2018 | 3365 | 0.49 | Why? |
| Community Health Services | 1 | 2020 | 1000 | 0.43 | Why? |
| Immune System | 1 | 2019 | 1479 | 0.39 | Why? |
| Anti-HIV Agents | 2 | 2019 | 2209 | 0.38 | Why? |
| CD8-Positive T-Lymphocytes | 2 | 2018 | 5837 | 0.35 | Why? |
| Retroviridae Infections | 2 | 2017 | 45 | 0.34 | Why? |
| Gene Expression | 1 | 2017 | 3332 | 0.33 | Why? |
| Point-of-Care Testing | 1 | 2020 | 2782 | 0.32 | Why? |
| Interleukins | 2 | 2021 | 762 | 0.26 | Why? |
| Antibodies | 2 | 2019 | 846 | 0.23 | Why? |
| Friend murine leukemia virus | 2 | 2017 | 29 | 0.22 | Why? |
| Interleukin-3 | 1 | 2021 | 35 | 0.22 | Why? |
| CD40 Ligand | 1 | 2021 | 121 | 0.22 | Why? |
| Cell Respiration | 1 | 2019 | 26 | 0.20 | Why? |
| Immunity, Heterologous | 1 | 2020 | 129 | 0.20 | Why? |
| Mass Screening | 1 | 2020 | 8005 | 0.20 | Why? |
| Leukemia, Experimental | 1 | 2017 | 3 | 0.18 | Why? |
| Glycolysis | 1 | 2019 | 208 | 0.18 | Why? |
| Receptors, CXCR5 | 1 | 2017 | 35 | 0.18 | Why? |
| Complement System Proteins | 2 | 2019 | 380 | 0.18 | Why? |
| Immunologic Surveillance | 1 | 2018 | 69 | 0.18 | Why? |
| Fas Ligand Protein | 1 | 2017 | 69 | 0.17 | Why? |
| HIV Antigens | 1 | 2018 | 102 | 0.17 | Why? |
| Lymphoid Tissue | 1 | 2018 | 162 | 0.17 | Why? |
| Enterotoxins | 1 | 2017 | 115 | 0.17 | Why? |
| Immunity, Humoral | 3 | 2020 | 4849 | 0.17 | Why? |
| Receptors, IgG | 1 | 2020 | 578 | 0.16 | Why? |
| Emtricitabine | 1 | 2017 | 202 | 0.16 | Why? |
| Tumor Virus Infections | 1 | 2017 | 127 | 0.16 | Why? |
| CTLA-4 Antigen | 1 | 2017 | 282 | 0.15 | Why? |
| Cytotoxicity, Immunologic | 1 | 2017 | 287 | 0.15 | Why? |
| Polymerase Chain Reaction | 2 | 2020 | 6740 | 0.14 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.14 | Why? |
| env Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 386 | 0.14 | Why? |
| Immunoglobulin Fc Fragments | 1 | 2018 | 691 | 0.14 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.13 | Why? |
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 952 | 0.13 | Why? |
| Germany | 4 | 2021 | 9196 | 0.13 | Why? |
| Immunoglobulin G | 4 | 2021 | 21571 | 0.12 | Why? |
| Programmed Cell Death 1 Receptor | 1 | 2017 | 724 | 0.12 | Why? |
| Cross Reactions | 2 | 2021 | 4374 | 0.12 | Why? |
| Complement Activation | 1 | 2019 | 949 | 0.12 | Why? |
| Immunophenotyping | 1 | 2017 | 1290 | 0.12 | Why? |
| Cell Proliferation | 1 | 2019 | 1973 | 0.11 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.11 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.11 | Why? |
| Polysaccharides | 1 | 2018 | 854 | 0.10 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.10 | Why? |
| High-Throughput Screening Assays | 1 | 2019 | 1783 | 0.10 | Why? |
| Family Characteristics | 1 | 2020 | 2551 | 0.10 | Why? |
| Interferon-alpha | 1 | 2017 | 1442 | 0.10 | Why? |
| Antibodies, Neutralizing | 4 | 2021 | 25288 | 0.10 | Why? |
| Immunologic Memory | 1 | 2021 | 3362 | 0.09 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.09 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2017 | 1138 | 0.09 | Why? |
| Hospitals, University | 1 | 2020 | 4173 | 0.09 | Why? |
| Killer Cells, Natural | 1 | 2018 | 2093 | 0.09 | Why? |
| Interferon-gamma | 1 | 2017 | 2711 | 0.08 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2017 | 2483 | 0.08 | Why? |
| Personnel, Hospital | 1 | 2020 | 2273 | 0.08 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.08 | Why? |
| Humans | 23 | 2021 | 930598 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 7868 | 0.08 | Why? |
| Transcriptome | 1 | 2018 | 3466 | 0.07 | Why? |
| Mice | 3 | 2021 | 21357 | 0.07 | Why? |
| Mice, Inbred C57BL | 3 | 2021 | 5542 | 0.07 | Why? |
| Glycosylation | 2 | 2018 | 1255 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2020 | 4239 | 0.07 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.06 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.06 | Why? |
| Sensitivity and Specificity | 2 | 2021 | 22971 | 0.06 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.06 | Why? |
| Adult | 7 | 2021 | 244371 | 0.06 | Why? |
| HL-60 Cells | 1 | 2020 | 60 | 0.06 | Why? |
| Chemokine CXCL12 | 1 | 2021 | 74 | 0.06 | Why? |
| Female | 10 | 2021 | 380317 | 0.05 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.05 | Why? |
| Flow Cytometry | 2 | 2019 | 2393 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2020 | 13720 | 0.05 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.05 | Why? |
| Viral Load | 3 | 2021 | 15850 | 0.05 | Why? |
| Mice, Inbred BALB C | 2 | 2021 | 5814 | 0.05 | Why? |
| Male | 7 | 2021 | 367725 | 0.05 | Why? |
| Animals | 5 | 2021 | 78931 | 0.05 | Why? |
| Cytokines | 2 | 2018 | 15010 | 0.05 | Why? |
| Guinea Pigs | 1 | 2019 | 420 | 0.05 | Why? |
| Prevalence | 1 | 2020 | 25773 | 0.05 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.04 | Why? |
| Receptors, Fc | 1 | 2018 | 153 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 3 | 2020 | 253789 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Aged | 4 | 2021 | 215776 | 0.04 | Why? |
| Gene Expression Profiling | 2 | 2018 | 3788 | 0.04 | Why? |
| Vaccination | 2 | 2018 | 19050 | 0.04 | Why? |
| Antibody-Dependent Cell Cytotoxicity | 1 | 2018 | 349 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Mice, Knockout | 1 | 2021 | 1815 | 0.04 | Why? |
| Vaccinia virus | 1 | 2018 | 346 | 0.04 | Why? |
| Systems Biology | 1 | 2018 | 320 | 0.04 | Why? |
| Protein Engineering | 1 | 2018 | 536 | 0.04 | Why? |
| Child | 2 | 2021 | 70012 | 0.03 | Why? |
| Aged, 80 and over | 2 | 2021 | 88759 | 0.03 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.03 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.03 | Why? |
| Cell Line | 2 | 2018 | 12040 | 0.03 | Why? |
| Pharynx | 1 | 2020 | 1544 | 0.03 | Why? |
| RNA, Viral | 1 | 2020 | 32276 | 0.03 | Why? |
| Dendritic Cells | 1 | 2021 | 1330 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2018 | 1326 | 0.03 | Why? |
| Sputum | 1 | 2020 | 1720 | 0.03 | Why? |
| Seroconversion | 1 | 2021 | 2515 | 0.03 | Why? |
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 2309 | 0.03 | Why? |
| HIV | 1 | 2018 | 1116 | 0.03 | Why? |
| Anti-Retroviral Agents | 1 | 2017 | 1099 | 0.02 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.02 | Why? |
| Disease Reservoirs | 1 | 2018 | 1672 | 0.02 | Why? |
| Bayes Theorem | 1 | 2018 | 3237 | 0.02 | Why? |
| Interferons | 1 | 2021 | 2885 | 0.02 | Why? |
| Neutralization Tests | 1 | 2021 | 6698 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.02 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2018 | 6049 | 0.02 | Why? |
| Epitopes | 1 | 2018 | 4113 | 0.02 | Why? |
| Binding Sites | 1 | 2018 | 6201 | 0.02 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2018 | 4020 | 0.02 | Why? |
| Immunity, Cellular | 1 | 2018 | 3614 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2018 | 4002 | 0.02 | Why? |
| Models, Molecular | 1 | 2018 | 7616 | 0.02 | Why? |
| T-Lymphocytes | 1 | 2021 | 6670 | 0.02 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.02 | Why? |
| Disease Models, Animal | 1 | 2021 | 10998 | 0.02 | Why? |
| Computational Biology | 1 | 2018 | 4514 | 0.02 | Why? |
| Immunity, Innate | 1 | 2021 | 6570 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.01 | Why? |
| Machine Learning | 1 | 2018 | 4395 | 0.01 | Why? |
| Antigens, Viral | 1 | 2018 | 6298 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Delivery of Health Care | 1 | 2021 | 15909 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Severity of Illness Index | 1 | 2021 | 48226 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |
| Health Personnel | 1 | 2021 | 29646 | 0.01 | Why? |
Streeck's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(159)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(167)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_